GSK to present new data from B-Together phase IIb trial at AASLD meeting

GSK plc announced it will present 14 abstracts at the American Association for the Study of Liver Diseases’ AASLD The Liver Meeting 2023, taking place in Boston, MA from November 10-14. Presentations feature data from two novel investigational specialty medicines, bepirovirsen, an antisense oligonucleotide for chronic hepatitis B, and linerixibat, an ileal bile acid transporter inhibitor for cholestatic pruritus in primary biliary cholangitis, or PBC. Key data include the first oral presentation of full results from the B-Together phase IIb trial investigating bepirovirsen followed by pegylated interferon alfa as treatment for people with CHB on nucleos(t)ide analogue therapy, the company noted. Chris Corsico, SVP, Development, GSK said: “We’re looking forward to highlighting research in a variety of serious liver conditions, stemming from our expertise in infectious disease, immunology and human genetics. Our presentations include new data for bepirovirsen which not only further our understanding of its durability of response and role as a future backbone of chronic hepatitis B treatment, but also improve our understanding of the heterogeneous nature of hepatitis B infections. These data across chronic liver diseases demonstrate our enduring commitment to ultimately improve patient care.”